Información de VolitionRX Ltd, dividendo de VolitionRX Ltd, actividades de los accionistas y más

Más Datos de VolitionRX Ltd Compañía

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Información de VolitionRX Ltd



Símbolo de cotizaciónVNRX

Nombre de la empresaVolitionRX Ltd

Fecha de salida a bolsaFeb 06, 2015

Director ejecutivoButera (Salvatore Thomas)

Número de empleados85

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 06

Dirección1489 West Warm Springs Road

CiudadHENDERSON

Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex

PaísUnited States of America

Código postal89014

Teléfono17024251561

Sitio Webhttps://volition.com/

Símbolo de cotizaciónVNRX

Fecha de salida a bolsaFeb 06, 2015

Director ejecutivoButera (Salvatore Thomas)

Ejecutivos de VolitionRX Ltd



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Guy Archibald Innes

Independent Director

196.86K

+5.92%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

133.66K

+10.94%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

31.97K

+31.59%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

31.19K

-0.85%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

21.20K

+40.80%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

18.94K

+14.10%

Mr. Nicholas Plummer

Group General Counsel

18.19K

-3.54%

Mr. Gael Forterre

Chief Commercial Officer

16.56K

-2.28%

Ms. Kim Nguyen

Independent Director

16.19K

+61.15%

Mr. Rodney Gerard Rootsaert

Corporate Secretary

13.70K

-2.65%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Guy Archibald Innes

Independent Director

196.86K

+5.92%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

133.66K

+10.94%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

31.97K

+31.59%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

31.19K

-0.85%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

21.20K

+40.80%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

18.94K

+14.10%

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

Cotterford Co., Ltd.

7.42%

Lagoda Investment Management, L.P.

7.09%

The Lind Partners, LLC

2.76%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.65%

Otro

78.65%

Accionistas

Proporción

Cotterford Co., Ltd.

7.42%

Lagoda Investment Management, L.P.

7.09%

The Lind Partners, LLC

2.76%

Innes (Guy Archibald)

2.43%

Reynolds (Cameron John)

1.65%

Otro

78.65%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

11.58%

Corporation

8.04%

Individual Investor

7.07%

Investment Advisor/Hedge Fund

1.07%

Research Firm

0.17%

Hedge Fund

0.14%

Bank and Trust

0.03%

Otro

71.89%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

66

1.13M

13.93%

-209.80K

2025Q4

58

26.12M

21.27%

+1.98M

2025Q3

57

23.92M

20.70%

+1.72M

2025Q2

78

41.39M

40.30%

+860.69K

2025Q1

83

44.42M

46.85%

+2.70M

2024Q4

82

41.53M

44.82%

+1.50M

2024Q3

82

38.59M

41.90%

+9.42M

2024Q2

82

28.77M

32.86%

+105.49K

2024Q1

84

28.22M

34.52%

+1.47M

2023Q4

87

26.17M

37.10%

+183.39K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Cotterford Co., Ltd.

12.01M

8.73%

--

Feb 09, 2026

Lagoda Investment Management, L.P.

11.46M

8.34%

-1.02M

-8.20%

Dec 31, 2025

The Lind Partners, LLC

4.46M

3.25%

+4.46M

--

Feb 09, 2026

Innes (Guy Archibald)

3.94M

2.86%

+233.25K

+6.30%

Feb 26, 2026

Reynolds (Cameron John)

2.67M

1.94%

+292.42K

+12.28%

Feb 26, 2026

Concord International Inc.

1.01M

0.73%

--

Feb 09, 2026

Geode Capital Management, L.L.C.

963.99K

0.7%

+85.82K

+9.77%

Dec 31, 2025

Hughes (Terig)

639.35K

0.46%

+202.00K

+46.19%

Feb 26, 2026

Micallef (Jacob Vincent)

623.85K

0.45%

-5.31K

-0.84%

Mar 17, 2026

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Proporción0%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Apr 17, 2026

Merger

20→1

Fecha

Fecha ex-dividendo

Tipo

Relación

Apr 17, 2026

Merger

20→1